Artivion Q3 revenue $95.8M (+9% YoY); EBITDA $17.7M (+28%); guides FY $389-396M

ARTIVION, INC.

2024-Q3 EPS reported $0.07 revenue$291,229,000

Revenue $95.8M (+9% GAAP, +10% constant currency); net loss ($2.3M) ($0.05 EPS) vs ($9.8M) ($0.24) prior year.
Non-GAAP net income $5.0M ($0.12 EPS) vs $0.7M ($0.02); includes $2.4M foreign currency gains.
Adjusted EBITDA $17.7M (+28%); FY guidance narrowed to $389-396M revenue and $69-72M EBITDA.
On-X +15%, BioGlue +14%, stent grafts +12%; APAC +23% and LatAm +21% (constant currency +32%).
Regulatory milestones: AMDS PMA module submitted, BioGlue approved in China, NEXUS TRIOMPHE enrollment complete.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.